CN111233929B - Deuterated nucleoside analogue and preparation method and application thereof - Google Patents
Deuterated nucleoside analogue and preparation method and application thereof Download PDFInfo
- Publication number
- CN111233929B CN111233929B CN202010131240.0A CN202010131240A CN111233929B CN 111233929 B CN111233929 B CN 111233929B CN 202010131240 A CN202010131240 A CN 202010131240A CN 111233929 B CN111233929 B CN 111233929B
- Authority
- CN
- China
- Prior art keywords
- compound
- cov
- sars
- deuterium
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940127073 nucleoside analogue Drugs 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 241000711573 Coronaviridae Species 0.000 claims description 15
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 13
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 7
- 208000025721 COVID-19 Diseases 0.000 claims description 6
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 208000019202 Orthocoronavirinae infectious disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract description 21
- 229910052805 deuterium Inorganic materials 0.000 abstract description 21
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 12
- 239000001257 hydrogen Substances 0.000 abstract description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 6
- 229940002612 prodrug Drugs 0.000 abstract description 6
- 239000000651 prodrug Substances 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 12
- 206010037660 Pyrexia Diseases 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000526636 Nipah henipavirus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- -1 adenosine analog monophosphate amide Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-VGCLAIIRSA-N (2s)-2-amino-3,3,3-trideuteriopropanoic acid Chemical compound [2H]C([2H])([2H])[C@H](N)C(O)=O QNAYBMKLOCPYGJ-VGCLAIIRSA-N 0.000 description 1
- TZYRSLHNPKPEFV-UHFFFAOYSA-N 2-ethyl-1-butanol Chemical compound CCC(CC)CO TZYRSLHNPKPEFV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 206010025080 Lung consolidation Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000001975 deuterium Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000024829 digestive system symptom Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000009254 shuang-huang-lian Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a compound shown as a formula I, or a pharmaceutically acceptable salt or prodrug thereof, wherein R 1 ~R 35 Each independently selected from hydrogen or deuterium, and R 1 ~R 35 At least one of which is selected from deuterium. The invention further provides a preparation method and application of the compound. Experiments prove that the compound has obvious inhibition effect on SARS-CoV-2 and longer half-life than Reidesvir, and the invention has very good application prospect in preparing medicaments for treating and/or preventing the diseases caused by SARS-CoV-2.
Description
Technical Field
The invention belongs to the field of medicinal chemistry, and particularly relates to a deuterated nucleoside analogue, and a preparation method and application thereof.
Background
Coronaviruses (CoV) are a group of pathogenic microorganisms that pose serious hazards to humans. To date, a total of 7 human-infecting coronaviruses, SARS-CoV, MERS-CoV-2 (a novel coronavirus, also 2019-nCoV), HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, have been discovered in humans. The latter four coronaviruses cause only mild cold or diarrhea symptoms.
Whether SARS in 2003, MERS in 2012, or covi-19 (a disease caused by a novel coronavirus) outbreak lasting up to 2020, poses serious threats and impacts on people's life health worldwide. Severe Acute Respiratory Syndrome (SARS) is an acute respiratory infectious disease caused by SARS coronavirus (SARS-CoV), and the main clinical manifestations are as follows: the incubation period is 1 to 16 days, and is usually 3 to 5 days. The fever is the first symptom with acute onset and strong infectivity, the fever can be aversion to cold, the body temperature is usually over 38 ℃, the fever is irregular or atonic fever, heat is remained, and the like, the fever is Cheng Duowei for 1 to 2 weeks; with headache, muscular soreness, asthenia, and diarrhea. Dry cough and little sputum appear after 3 to 7 days of onset, blood streak sputum occasionally appears, and the sign of the lung is not obvious. The disease reaches the peak in 10-14 days, the symptoms of infection and poisoning such as fever, hypodynamia and the like are aggravated, frequent cough, shortness of breath, dyspnea and dyspnea appear, and asthma and palpitation are forced to rest in bed when the patient moves slightly. This stage is prone to secondary infections of the respiratory tract. After the course of disease is 2-3 weeks, fever gradually recedes, and other symptoms and physical signs are relieved or even disappear. The absorption and recovery of the inflammatory changes of the lung are slow, and the inflammatory changes of the lung can be completely absorbed and recovered after the normal body temperature is about 2 weeks. Mild patients have mild clinical symptoms. Severe patients are in serious condition and are prone to respiratory distress syndrome. The disease condition of children patients is lighter than that of adults. There are a few patients who do not have fever as the first symptom, especially patients with recent surgical history or underlying disease. In 2003, data published by the world health organization showed that 919 people died due to SARS worldwide, the fatality rate was approximately 11%. Middle East Respiratory Syndrome (MERS) is a serious respiratory disease caused by MERS-CoV, and the main symptoms include fever, cough, dyspnea, and the like, and digestive system symptoms such as diarrhea, nausea, vomiting, and the like may also occur, which may cause serious complications such as pneumonia and renal failure. MERS-CoV has led to infections in more than 2468 worldwide, deaths in more than 851, with MERS patient mortality around 38% according to the World Health Organization (WHO) statistics since 2012 (431/1139). According to the statistics of the World Health Organization (WHO), the mortality rate of MERS patients is about 38% (431/1139).
The disease caused by the novel coronavirus (COVID-19) is caused by infection with the novel coronavirus (SARS-CoV-2).
The general symptoms of SARS-CoV-2 infection are: fever, weakness, dry cough, and gradually dyspnea; some patients have slight onset symptoms and even no obvious fever. The severe symptoms are: acute respiratory distress syndrome, septic shock, uncorrectable metabolic acidosis, and hemorrhagic blood coagulation dysfunction. SARS-CoV-2 virus positive can be detected in nasopharyngeal swab, sputum, respiratory tract secretion, blood and excrement of SARS-CoV-2 infected patient, and the chest imaging of patient shows that it has multiple small spot images and change of interstitium in early stage, and has obvious extrapulmonary zone. Further, the lung develops into a double-lung and multiple-wear glass shadow and an infiltrative shadow, and the severe cases may have lung consolidation and pleural effusion rarely.
According to the diagnosis and treatment scheme (trial fifth edition) of pneumonia infected by novel coronavirus, no specific antiviral drug exists for treating the novel coronavirus infected patients clinically at present, isolation and support treatment is generally adopted for infected patients, but the atomization inhalation of alpha-interferon and lopinavir/ritonavir can be tried. The ongoing clinical trial drugs for 2019-nCoV include Chinese patent drugs (such as Shuanghuanglian) or anti-other virus drugs (such as Reddisivir (Remdisivir), abidol, darunavir and the like), which have the inhibiting effect on 2019-nCoV in vitro cell tests. Among them, the structure of Remdisivir (Remdisivir) is shown below, and has shown a better therapeutic effect in 1 U.S. patient infected with a novel Coronavirus (First Case of 2019Novel Coronavir in the United states, michelle, holshue, chase et al., new England,2020January 31DOI. Formally introduced into china in month 2 of 2020, a phase III clinical trial of novel coronavirus infection is currently underway.
Remdisivir (Remdisivir) is a novel adenosine analog monophosphate amide prodrug that is converted within the cell to the pharmacologically active form of Nucleoside Triphosphates (NTPs), which inhibit viral RNA polymerase and inhibit viral nucleic acid synthesis. Phase III clinical studies are currently underway for the treatment of ebola virus (Ebolavirus) infections. It has also been found to have broad-spectrum antiviral activity against various RNA viruses such as Respiratory Syncytial Virus (RSV), vernoninfrus, lassa fever virus, MERS-CoV, SARS, nipah virus (Nipahvirus) and the like in vitro.
The Rudexilvir compound is disclosed in Chinese patent CN103052631A (2016.2.24), and subsequently disclosed are application patents CN105899216A (2016.08.24), CN 107073005A (2017.08.18), CN107074902A (2017.08.18), CN108348526A (2018.07.31) and crystal form patent CN110636884A (2019.12.31).
The hydrogen in the active molecular group of the medicine is replaced by isotope deuterium, which is nontoxic and nonradioactive and is stabilized about 6-9 times than a carbon-hydrogen bond, so that the metabolic site can be sealed to prolong the half-life period of the medicine, the treatment dosage is reduced, and the pharmacological activity of the medicine is not influenced, thereby being considered as an excellent modification method.
At present, no research report on the deuterated products of the ridciclovir compounds exists, and in view of the important role of the ridciclovir compounds in controlling the epidemic situation of the novel coronavirus, the research on the deuterated products of the ridciclovir compounds further improves the in vivo metabolism of the ridciclovir compounds and expands the therapeutic window range has important clinical significance.
Disclosure of Invention
The invention aims to provide a deuterated nucleoside analogue, a preparation method and application thereof, in particular to a deuterated Redexilvir, a preparation method and application thereof.
The invention provides a compound shown in a formula I, or pharmaceutically acceptable salt thereof, or prodrug thereof,
R 1 ~R 35 each independently selected from hydrogen or deuterium, and R 1 ~R 35 At least one of which is selected from deuterium.
Further, the compound is shown as a formula II,
wherein R is 1 ~R 22 Each independently selected from hydrogen or deuterium, and R 1 ~R 22 At least one of which is selected from deuterium.
Further, the compound is shown as a formula III,
wherein R is 13 ~R 21 Each independently selected from hydrogen or deuterium, and R 13 ~R 21 At least one of which is selected from deuterium.
Further, in the formula III,
R 13 ~R 17 all being deuterium, R 18 ~R 21 Each independently selected from hydrogen or deuterium;
or R 19 ~R 21 All being deuterium, R 13 ~R 18 Each independently selected from hydrogen or deuterium;
or R 18 Selected from deuterium, R 13 ~R 17 And R 19 ~R 21 Each independently selected from hydrogen or deuterium.
Further, the compound is selected from the following structures:
further, the compound synthesis route is as follows:
wherein, the synthetic route comprises the following steps:
(1) Carrying out esterification reaction on the compound A and the compound B to obtain a compound C;
(2) Carrying out N-phosphorylation reaction on the compound C and the compound D; then adding a compound E to carry out nucleophilic substitution reaction to obtain a compound F;
(3) Reacting the compound F with the compound G under the action of a catalyst and an acid-binding agent to generate a compound H;
(4) Deprotecting the compound H to obtain a target product, a compound shown in formula III;
wherein R is 13 ~R 21 As defined in claim 3, R 36 Selected from hydrogen or deuterium.
Further, the air conditioner is characterized in that,
in the step (1), the catalyst used in the esterification reaction is thionyl chloride, the molar ratio of the thionyl chloride to the compound A is 1.0-2.0, the reaction temperature is 20-80 ℃, and the reaction time is 4-8 h;
in the step (2), the organic solvent is dichloromethane; dripping the compound D and triethylamine at-78 ℃, reacting at 0-25 ℃ for 3-6 h, and monitoring the completion of the conversion of the compound C by HPLC, wherein the HPLC conditions are as follows: mobile phase 10% acetonitrile (containing 0.05% triethylamine): 90% of water (containing 0.05% of triethylamine), the time is 10min, the flow rate is 1.0mL/min, the column temperature is 30 ℃, the column is Welch Ultimate AQ-C18,5um,4.6x200mm, then 4-nitrophenol and triethylamine are added at 0-10 ℃, the temperature is kept and stirred for 2-4 h at 10-20 ℃, the reaction solution is decompressed and concentrated at 20-25 ℃ to remove the organic solvent, the concentrate is separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate = 8:1) to obtain a crude racemate product of the compound F, the crude product is pulped and filtered by diisopropyl ether, wherein the using volume of the diisopropyl ether is 2-6 times of the weight of the crude product, preferably 4 times of the volume, and the filter cake is dried for 4h under vacuum at 40-50 ℃ to obtain the optically pure compound F;
in the step (3), the used organic solvent can be acetonitrile, tetrahydrofuran and toluene, preferably acetonitrile, the used catalyst can be magnesium chloride, zinc chloride, stannic chloride and stannous chloride, preferably magnesium chloride, the acid-binding agent can be triethylamine, pyridine and N, N-diisopropylethylamine, preferably N, N-diisopropylethylamine, the reaction temperature is 50-80 ℃, the reaction time is 0.5-2H, the reaction liquid is decompressed and concentrated to remove the organic solvent, ethyl acetate is added into the concentrate, the obtained solution is washed by 5% sodium citrate, saturated ammonium chloride solution, 5% sodium bicarbonate solution and saturated salt solution in sequence, and the compound H is obtained by silica gel column chromatography (petroleum ether: ethyl acetate = 4:1) after the organic phase is concentrated;
in the step (4), the organic solvent can be selected from acetonitrile, tetrahydrofuran and acetone, the reagent is hydrochloric acid, the molar ratio of the hydrochloric acid to the compound H is 1.0-1.5, the reaction temperature is 0-15 ℃, and the reaction time is 1-3H. After the reaction is finished, dropwise adding saturated sodium bicarbonate aqueous solution at 0-5 ℃ to adjust the pH value to 7-8, extracting the reaction solution by ethyl acetate, washing an organic phase by saturated saline solution, decompressing and concentrating to obtain a crude product, and separating and purifying by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain the target compound, namely the compound shown in the formula III.
The present invention provides the use of a compound, or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament against a coronavirus selected from MERS-CoV, SARS-CoV-2, more preferably the virus is SARS-CoV-2.
The invention provides application of a compound or a pharmaceutically acceptable salt thereof or a prodrug thereof in preparing a medicament for preventing and/or treating a coronavirus infection disease, wherein the coronavirus infection disease is selected from MERS, SARS and COVID-19, and the COVID-19 is preferred.
The invention provides a pharmaceutical composition, which is characterized in that: the pharmaceutical composition is a preparation prepared from the compound, or pharmaceutically acceptable salt or prodrug thereof and pharmaceutically acceptable auxiliary materials.
On the basis of maintaining the effectiveness of the compound on SARS-CoV-2, the compound obviously prolongs the half-life period, reduces the requirement on dosage, reduces side effects and enlarges the treatment window range, so the compound has very good prospect for preparing the medicine for treating the diseases related to coronavirus infection
Deuterium in the context of the present invention is an isotope of hydrogen (H), also known as deuterium, and the symbol of the element is generally D or 2 H, the deuterium nucleus has one proton and one neutron with a relative atomic weight of 2.
The term "deuteron" as used herein refers to a product wherein at least one hydrogen in the molecule is replaced by deuterium.
The pharmaceutically acceptable salt is a product obtained by directly salifying the free base of the compound and an inorganic or organic acid. Wherein the inorganic or organic acid is selected from hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, picric acid, citric acid, maleic acid, methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, etc.
It will be apparent that various other modifications, substitutions and alterations can be made in the present invention without departing from the basic technical concept of the invention as described above, according to the common technical knowledge and common practice in the field.
Detailed Description
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
The raw materials and equipment used in the invention are known products and are obtained by purchasing commercial products. EXAMPLE 1 preparation of Compound 1 of the present invention
The synthetic route is as follows:
the preparation method comprises the following steps:
adding L-alanine-3,3,3-d 3 (A-1, 1.00g, 0.011mol) and 2-ethylbutanol (B, 10 mL) into a reaction bottle, stirring the reaction system at 0 ℃ for 5min, slowly adding thionyl chloride (1.44g, 0.012mol), heating to 60 ℃, stirring and keeping the temperature and stirring for 6h, reducing concentration to remove most of solvent, cooling the concentrate to room temperature, adding 30mL of ethyl acetate and stirring for 60min, and performing suction filtration to obtain a white-like solid, namely the compound C-1 (2.11 g, the yield is 90.2%, and the mass spectrometric detection abundance is 99.3atom D).
The mixture of Compound C-1 (1.50g, 0.007mol) and dichloromethane (30 mL) was cooled to-78 deg.C with stirring, and benzyloxydichlorophosphate (D, 1.48g, 0.007mol) was added, followed by slow dropwise addition of triethylamine (0.71g, 0.007mol). The system was warmed to 20 ℃ and stirred at the same temperature for 5h, and HPLC monitored for completion (10% acetonitrile (containing 0.05% TFA): 90% water (containing 0.05% TFA), 10min,1.0mL/min,30 ℃, welch Ultimate AQ-C18,5um, 4.6x200mm). The system was cooled to 0 ℃ and 4-nitrophenol (E, 0.88g, 0.006 mol) was added, then triethylamine (0.71g, 0.007mol) was slowly added dropwise, the reaction warmed to 20 ℃ and stirred for 3h. After the reaction, the solvent was removed by concentration under reduced pressure at 20 to 25 ℃, and the concentrate was separated by silica gel column chromatography (petroleum ether-ethyl acetate = 8:1) to obtain colorless semisolid (2.27g, 71.5%). The obtained semi-solid is stirred with 10mL of diisopropyl ether for 24h and then is filtered, the filter cake is a compound F-1, and the compound F-1 is dried in vacuum for 4h at 40 ℃ to obtain 0.86g, and the yield is 38.0%. 1 H-NMR(400MHz,DMSO-d6): δ8.37-8.29(m,2H),7.55-7.49(m,2H),7.48-7.40(m,2H),7.29-7.21 (m,3H),6.71(m,1H),4.12-4.07(m,1H),4.01(d,J=5.7Hz,2H),1.43(m, 1H),1.31-1.21(m,4H),0.80(t,J=7.4Hz,6H);LCMS m/z 454.2[M+H].
Taking a compound F-1 (0.65g, 0.001mol), a compound G (0.33g, 0.001mol), magnesium chloride (0.10g, 0.001mol) and 10mL of acetonitrile, stirring at 50 ℃ for 10min, then adding N, N-diisopropylethylamine (0.39g, 0.003mol), stirring for 20min, cooling to 20 ℃, concentrating at 30-40 ℃ under reduced pressure to remove the acetonitrile, then adding 100mL of ethyl acetate, washing the reaction solution with a 5% citric acid aqueous solution (20 mL), a saturated ammonium chloride aqueous solution (20 mL), a 5% sodium bicarbonate aqueous solution (20 mL) and a saturated saline solution (20 mL), concentrating the organic phase under reduced pressure, and performing column chromatographyThe product was purified by chromatography (petroleum ether-ethyl acetate = 4:1) to give compound H-1 (0.47g, 73.0%) as an off-white solid. 1 H-NMR(400MHz,methanol-d4):δ7.89 (s,1H),7.28–7.23(m,2H),7.09–7.05(m,3H),6.83(m,2H),5.30(d,J= 6.6Hz,1H),4.91(m,1H),4.57-4.51(m,1H),4.35-4.22(m,2H),4.00(m, 1H),3.89(m,1H),3.80(m,1H),1.60(s,3H),1.49-1.43(m,1H),1.40(s, 3H),1.36-1.23(m,4H),0.86(t,J=7.4Hz,6H);LCMS m/z 646.1[M+H].
Taking a compound H-1 (0.40g, 0.0006 mol) and 10mL THF, stirring the system, cooling to 5 ℃, then dropwise adding concentrated hydrochloric acid (0.07g, 0.0007 mol), keeping the temperature for 5 ℃, stirring for 2H, adding 5mL water, adjusting the pH to 7-8 by using a saturated sodium bicarbonate solution, extracting the system by using ethyl acetate (10mL x 2), washing by using saturated saline water (5 mL), decompressing and concentrating to obtain a white-like solid, namely a compound 1 crude product, and purifying by using column chromatography (petroleum ether-ethyl acetate = 2:1) to obtain 0.27g, wherein the yield is 75.0%. 1 H NMR(400MHz,CD3OD):7.81(s,1H),7.31-7.25 (m,2H),7.20-7.07(m,3H),6.91-6.80(m,2H),1.49-1.38(m,1H),1.32-1.21(m,4H),0.84(m,6H).LCMS m/z 606.1[M+H].
EXAMPLES 2-7 preparation of Compounds 2-7
The preparation of the compounds 2 to 7 selects different substrates A series and D series, and adopts the synthetic route and the operation steps of the compound 1 to prepare the compound, which is shown in the table 1.
TABLE 1 preparation of Compounds 2 to 7
The beneficial effects of the compounds of the present invention are demonstrated by the following experimental examples.
Experimental example 1 Effect of the Compound of the present invention on SARS-CoV-2 in HAE cell System
1. Experimental methods
HAE cells were plated in 384-well plates and cultured for 24 hours.
SARS-CoV-2 was inoculated onto the culture plate, and the cells were cultured at 37 ℃ for 72 hours. Compounds 1-7 of the present invention and Remdisivir were administered separately. And 24 hours later, detecting the virus factors. And calculate the median effective concentration EC50.
2. The results are shown in Table 2
TABLE 2 effectiveness of the compounds of the invention against SARS-CoV-2
Compound (I) | EC50(um) |
Remdisivir | 0.050 |
Compound 1 | 0.061 |
Compound 2 | 0.051 |
Compound 3 | 0.073 |
Compound 4 | 0.066 |
Compound 5 | 0.053 |
Compound 6 | 0.064 |
Compound 7 | 0.070 |
From the above results, it can be seen that the in vitro efficiency of compounds 1 to 7 of the present invention, i.e., deuterium substitution of specific structure of Remdisivir, against SARS-CoV-2 is comparable to Remdisivir, wherein the in vitro efficiency of compounds 2 and 5 against SARS-CoV-2 is almost unchanged, and the effectiveness of Remdisivir is retained.
EXAMPLE 2 study of the half-Life of the Compound of the present invention in animals
Taking 10 SD rats, adopting tail vein injection to carry out administration of the compounds 1-7 and Remdisivir, collecting blood at 8 time points for each animal, drawing a blood concentration curve, and calculating the half-life period of the drug according to the result.
The test results are shown in Table 3.
TABLE 3 in vivo half-life results for the compounds of the invention in animals
Through half-life test results, it can be seen that the compound 1 and the compound 2 of the present invention realize the effect of prolonging the half-life of Remdisivir by deuterium substitution at a specific position, and the prolonging effects are that the compound 1 is prolonged by 13.2% and the compound 2 is prolonged by 26.7%, respectively. The half-life of the compounds 3-5 is basically equivalent to that of Remdisivir, the compounds 3 and 5 are slightly longer, and the half-life of the compounds 6-7 is slightly shorter than that of Remdisivir.
In conclusion, on the basis of keeping the effectiveness on SARS-CoV-2, the compounds 1 and 2 of the invention remarkably prolong the half-life period, reduce the requirement on dosage, reduce side effects and enlarge the treatment window range, therefore, the invention has very good prospect for preparing the medicine for treating the diseases related to coronavirus infection.
Claims (6)
2. use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for combating a coronavirus selected from MERS-CoV, SARS-CoV-2.
3. Use according to claim 2, wherein the coronavirus is SARS-CoV-2.
4. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention and/or treatment of a disease caused by a coronavirus infection selected from MERS, SARS, COVID-19.
5. The use according to claim 4, wherein the coronavirus infectious disease is COVID-19.
6. A pharmaceutical composition characterized by: the pharmaceutical composition is a preparation prepared from the compound or the pharmaceutically acceptable salt of the compound of claim 1 and pharmaceutically acceptable auxiliary materials.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010131240.0A CN111233929B (en) | 2020-02-28 | 2020-02-28 | Deuterated nucleoside analogue and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010131240.0A CN111233929B (en) | 2020-02-28 | 2020-02-28 | Deuterated nucleoside analogue and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111233929A CN111233929A (en) | 2020-06-05 |
CN111233929B true CN111233929B (en) | 2023-02-28 |
Family
ID=70876687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010131240.0A Active CN111233929B (en) | 2020-02-28 | 2020-02-28 | Deuterated nucleoside analogue and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111233929B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI811812B (en) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | Phospholipid compounds and uses thereof |
CN114621287A (en) * | 2020-12-11 | 2022-06-14 | 中国科学院大连化学物理研究所 | Deuterated Dardisivir compound, and synthesis method and application thereof |
CN114634529A (en) * | 2020-12-15 | 2022-06-17 | 中国科学院大连化学物理研究所 | Fluororeiciclovir and synthesis method thereof |
CN112661801A (en) * | 2020-12-18 | 2021-04-16 | 成都阿奇生物医药科技有限公司 | Nucleoside analogue and deuteron thereof, and preparation method and application thereof |
CN114478151B (en) * | 2022-01-13 | 2024-01-12 | 浙江爱索拓科技有限公司 | Radioisotope carbon-14 labeled adefovir and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108348526A (en) * | 2015-09-16 | 2018-07-31 | 吉利德科学公司 | The method for treating Arenaviridae and coronaviridae virus infection |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015025766A2 (en) * | 2013-04-12 | 2017-10-17 | Achillion Pharmaceuticals Inc | highly active nucleoside derivative for the treatment of hcv |
-
2020
- 2020-02-28 CN CN202010131240.0A patent/CN111233929B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108348526A (en) * | 2015-09-16 | 2018-07-31 | 吉利德科学公司 | The method for treating Arenaviridae and coronaviridae virus infection |
Non-Patent Citations (2)
Title |
---|
First Case of 2019 Novel Coronavirus in the United States;Michelle L. Holshue et al.;《The New England Journal of Medicine》;20200131;第328卷(第10期);第935页第6段 * |
氘代药物研发的过去、现在与未来;张寅生;《药学进展》;20171231;第41卷(第12期);第902-918页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111233929A (en) | 2020-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111233929B (en) | Deuterated nucleoside analogue and preparation method and application thereof | |
CN114426568B (en) | 2-oxo-3-pyrrolidinyl propionitrile compounds, pharmaceutical composition and application thereof | |
JP6989509B2 (en) | Aryl-substituted pyrimidines for use in influenza virus infection | |
JP2013535453A (en) | Methods and compounds for treating Paramyxoviridae viral infections | |
JP2013139483A (en) | Therapeutic agent for influenza | |
CN108676067B (en) | A kind of noval chemical compound and preparation method thereof of pre- preventing HIV infection | |
JP2022500375A (en) | Pyridopyrazine and pyridotriazine influenza virus replication inhibitors | |
CN115466225A (en) | Amide compound, preparation method, pharmaceutical composition and application thereof | |
CN112771048B (en) | Inhibitors of influenza virus replication and intermediates and uses thereof | |
KR20150017734A (en) | Fluorosubstituted (3R,4R,5S)-5-guanidino-4-acetamido-3-(pentan-3-yloxy)cyclohexene-1- carboxylic acids, their esters and use thereof | |
CN110156628B (en) | Cyclotriol derivative and preparation method and application thereof | |
CN110240624B (en) | Androstane derivative and preparation method and application thereof | |
JP2000007695A (en) | New arabinosyladenine derivative | |
CN111909174B (en) | Crystal form of pyridone derivative, preparation method and application | |
CN112661801A (en) | Nucleoside analogue and deuteron thereof, and preparation method and application thereof | |
CN108299316B (en) | Anti-influenza virus compound and preparation method and application thereof | |
CN101468958B (en) | Novel ethylene diamine derivative | |
US20240083884A1 (en) | Compounds and method for preparing the same | |
CN101284811A (en) | Synthetic method for chiral carbocyclic ring intermediate of abacavir | |
CN114105807B (en) | Hydroxycyclohexanamide compound and preparation method and application thereof | |
WO2024098856A1 (en) | Anti-influenza-virus derivatives and use thereof | |
CN109810063A (en) | A kind of novel resisiting influenza virus " twin medicine ", preparation method and the usage | |
CN116284048B (en) | Compound and preparation method, pharmaceutical composition and application thereof | |
CN112079785A (en) | Novel anti-influenza virus oseltamivir derivative, preparation method and application thereof | |
US20230365535A1 (en) | Compounds and method for preparing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |